AbbVie/$ABBV
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Ticker
$ABBV
Sector
Primary listing
NYSE
Employees
55,000
Headquarters
Website
AbbVie Metrics
BasicAdvanced
$374B
160.50
$1.32
0.51
$6.47
3.09%
Price and volume
Market cap
$374B
Beta
0.51
52-week high
$244.81
52-week low
$163.81
Average daily volume
6M
Dividend rate
$6.47
Financial strength
Total debt to equity
-51,148.551
Interest coverage (TTM)
6.22%
Profitability
EBITDA (TTM)
28,500
Gross margin (TTM)
71.20%
Net profit margin (TTM)
4.00%
Operating margin (TTM)
33.95%
Effective tax rate (TTM)
-44.28%
Revenue per employee (TTM)
$1,080,000
Management effectiveness
Valuation
Price to earnings (TTM)
160.502
Price to revenue (TTM)
6.287
Price to book
-2,046.02
Price to tangible book (TTM)
-4.03
Dividend yield (TTM)
3.05%
Forward dividend yield
3.09%
Growth
Revenue change (TTM)
7.40%
Earnings per share change (TTM)
-53.98%
3-year revenue growth (CAGR)
1.04%
10-year revenue growth (CAGR)
10.53%
3-year earnings per share growth (CAGR)
-43.95%
10-year earnings per share growth (CAGR)
-2.63%
3-year dividend per share growth (CAGR)
5.17%
10-year dividend per share growth (CAGR)
12.50%
What the Analysts think about AbbVie
Analyst ratings (Buy, Hold, Sell) for AbbVie stock.
Bulls say / Bears say
AbbVie’s stock jumped 4% to a record high after securing exclusivity for Rinvoq until 2037, extending protection against generic competition and supporting multi-billion-dollar revenue visibility (Reuters)
In a head-to-head Phase 3 trial, Rinvoq outperformed Humira—43.3% vs. 22.4% of patients achieved clinical improvement—bolstering confidence in AbbVie’s shift toward newer immunology assets (Reuters)
Management raised its 2025 profit outlook in July, citing strong Skyrizi and Rinvoq sales and noting that AbbVie’s tariff exposure is “fairly insulated” by domestic manufacturing, reducing policy risk to margins (Reuters)
The $2.7 billion third-quarter 2025 in-process R&D charge forced AbbVie to cut its full-year adjusted EPS guidance to $10.38–10.58, well below the prior $11.88–12.08 range and analysts’ $12.02 forecast, highlighting significant pipeline investment risks (Reuters)
Second-quarter 2025 Humira sales of $1.18 billion missed Street estimates of $1.45 billion as biosimilar competition accelerated erosion of the franchise, pressuring a core revenue stream (Reuters)
Guidance excludes any impact from pending U.S. sector-specific import duties, leaving potential downside if pharmaceutical tariffs are imposed, as management’s forecast assumes no tariff-related costs (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2025.
AbbVie Financial Performance
Revenues and expenses
AbbVie Earnings Performance
Company profitability
AbbVie News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for AbbVie stock?
AbbVie (ABBV) has a market cap of $374B as of November 04, 2025.
What is the P/E ratio for AbbVie stock?
The price to earnings (P/E) ratio for AbbVie (ABBV) stock is 160.5 as of November 04, 2025.
Does AbbVie stock pay dividends?
Yes, the AbbVie (ABBV) stock pays dividends to shareholders. As of November 04, 2025, the dividend rate is $6.47 and the yield is 3.09%. AbbVie has a payout ratio of 0% on a trailing twelve-month basis.
When is the next AbbVie dividend payment date?
The next AbbVie (ABBV) dividend payment is scheduled for November 14, 2025.
What is the beta indicator for AbbVie?
AbbVie (ABBV) has a beta rating of 0.51. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.